A study of NVX-108 (Perflenapent) in patients with hypoxic solid brain tumor, glioblastoma multiforme (GBM).
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Perflenapent (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 29 Sep 2017 According to National Cancer Institute media release, National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate this trial.
- 28 Aug 2017 According to a NuvOx Pharma media release, this trial will be led by Dr. Baldassarre Stea from the University of Arizona. The trial will be conducted at Banner MD Anderson, Banner-University Medical Center Tucson, Barrow Neurological Institute and Miami Cancer Institute.
- 18 Apr 2017 New trial record